Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993587 | 0.83 | MPO (0.35) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL237848 | 0.83 | RET (0.39) | KDM4EALDH1A1GAA | |
| SCHEMBL4986900 | 0.79 | HTR1A (0.49) | CYP1A2 | |
| SCHEMBL12861068 | 0.79 | ALDH1A1 (0.44) | RAB9ANPC1KDM4ETSHRALDH1A1 | |
| SCHEMBL242255 | 0.79 | ACHE (0.44) | KDM4ETSHRALDH1A1HPGDCYP1A2 | |
| SCHEMBL13996245 | 0.76 | KMT2A (0.37) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL13993585 | 0.75 | CLK1 (0.35) | CLK1RAB9ANPC1KDM4ETSHR | |
| SCHEMBL3266921 | 0.73 | NPC1 (0.33) | CLK1RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL13993583 | 0.72 | CYP1A2 (0.43) | CLK1RAB9ANPC1KDM4ETSHR | |
| SCHEMBL243637 | 0.72 | CLK1 (0.48) | CLK1RAB9ANPC1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468366-B2 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468366-B2 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1453812-B1 | CYTOTOXIC AGENTS | UNIV RUTGERS (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050009825-A1 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-01-13 | — | — | US | disclosed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009825-A1 | Cytotoxic agents | TOP1, TOP2A, TOP2B | CLK1 3833/4885TLR8 4080/4885RAB9A 3543/4885 |
| US-20080090831-A1 | CYTOTOXIC AGENTS | TOP1, TOP2A, TOP2B | CLK1 3833/4885TLR8 4080/4885RAB9A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.